Stay updated with breaking news from Sophia hergenhan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
DiosCURE to Develop Highly Specific Single-Chain Antibodies Against SARS-CoV-2, Lead Candidates Described in Science Publication Core technology includes promising bivalent single-domain antibodies simultaneously targeting two surface structures of the viral spike protein. Lead candidates DIOS-202 and DIOS-203 are engineered for high potency and their potential to avoid the emergence of escape mutants. DIOS-202 and DIOS-203 entered into accelerated development to initiate clinical studies later this year. DiosCURE Therapeutics SE announced a publication in Science describing its core technology of multivalent single-chain antibodies with a unique molecular mode-of-action to inactivate SARS-CoV-2 virions. An international team led by scientists at the University of Bonn developed and characterized the lead candidates, which are exclusively licensed by DiosCURE. ....
Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms - First joint CriVac® vaccine candidate to target receptor-binding domain of SARS-CoV-2 - Evaluation of Cristal s CliCr® and Intravacc s OMV technology News provided by Share this article , a world leader in translational research and development of vaccines, and Cristal Therapeutics, a technology leader in enabling safer and more effective therapeutics, today announced a strategic collaboration to develop novel vaccine programs against human diseases with the initial candidate targeting COVID-19. (PRNewsfoto/Intravacc B.V.) Under the terms of the agreement, Cristal Therapeutics and Intravacc will collaborate with an initial focus on generating a CriVac ....
Immunicum AB (publ) Announces Completion of Patient Recruitment for Phase Ib Portion of ILIAD Combination Clinical Trial 17 December 2020 Immunicum AB (publ) Announces Completion of Patient Recruitment for Phase Ib Portion of ILIAD Combination Clinical Trial Topline results on safety and dosing from Phase Ib portion of trial expected during Q3 2021 Phase II portion of trial can initiate following selection of dose regimen from Phase Ib trial Immunicum AB (publ; IMMU.ST) announced today the completion of patient recruitment for the Phase Ib portion of the ongoing ILIAD (ILIxadencel in combination with checkpoint inhibitors in ADvanced cancer patients) trial. The primary objective of the Phase Ib study is to evaluate the safety and tolerability as well as define the dose regimen for Immunicum s lead cell-based candidate, ilixadencel, in combination with the checkpoint inhibitor (CPI), Keytruda (pembrolizumab), in a total of 21 patients. ....